NATH BIO-GENES (I) LTD (NATHBIOGEN) financials

NATH BIO-GENES (I) LTD (NATHBIOGEN) NSE/BSE financials on Fincrux: quarterly results, profit and loss, cash flow, balance sheet, ratios, and shareholding.

Incorporated in 1993, Nath Bio-Genes Ltdis in the business of Production, Processing,and Marketing of Hybrid and GM Seeds[1]

Market Cap: ₹262Cr.
Current Price: ₹138
Stock P/E: 6.01
ROE: 5.70%
ROCE: 7.23%
Book Value: ₹363
Dividend Yield: 1.45%
52W High / Low: ₹207/126

In Jun 2026, NATH BIO-GENES (I) LTD (NATHBIOGEN) reported sales ₹323 Cr and net profit ₹33 Cr.

Annual TTM: sales ₹474 Cr, net profit ₹48 Cr.

Shareholding: Promoters 45.59% (Jun 2026), FIIs 0.26% (Jun 2026), DIIs 0.01% (Jun 2026), Public 54.13% (Jun 2026), No. of Shareholders 32,564% (Jun 2026).

NATHBIOGEN quarterly results (₹ Cr.)
Category	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	32	37	49	280	40	66	46	323
Expenses	26	29	46	250	33	57	39	288
Operating Profit	7	8	3	30	7	9	7	35
OPM %	20%	20%	6%	11%	18%	13%	14%	11%
Other Income	0	0	5	4	2	4	4	3
Interest	3	3	1	3	3	4	3	4
Depreciation	1	1	1	1	1	1	1	1
Profit before tax	3	4	5	30	5	8	6	33
Tax %	-1%	30%	12%	2%	13%	11%	40%	2%
Net Profit	3	3	5	29	4	7	4	33
EPS in Rs	1.52	1.40	2.48	15.37	2.21	3.80	1.99	17.19
Raw PDF	—	—	—	—	—	—	—	—

NATHBIOGEN profit and loss (₹ Cr.)
Category	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	246	271	230	234	248	265	345	474
Expenses	191	204	193	185	197	212	292	417
Operating Profit	55	67	37	49	50	53	53	58
OPM %	22%	25%	16%	21%	20%	20%	15%	12%
Other Income	2	2	-87	1	4	4	14	13
Interest	7	9	11	10	9	10	13	14
Depreciation	1	3	3	3	3	4	4	4
Profit before tax	49	57	-63	36	42	44	49	53
Tax %	-4%	2%	6%	3%	5%	4%	10%	—
Net Profit	50	56	-67	35	40	42	44	48
EPS in Rs	26.56	29.29	-35.43	18.51	21.14	22.17	23.38	25.19
Dividend Payout %	0%	7%	-6%	11%	9%	9%	9%	—

NATHBIOGEN balance sheet (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	19	19	19	19	19	19	19	19
Reserves	489	539	594	523	554	592	630	670
Borrowings	58	70	101	93	105	108	111	122
Other Liabilities	80	102	75	105	114	158	258	272
Total Liabilities	646	730	790	740	793	877	1,017	1,083
Fixed Assets	232	246	247	245	244	249	250	249
CWIP	0	0	0	0	0	0	0	0
Investments	5	5	5	5	5	6	6	6
Other Assets	409	479	538	490	544	622	761	827
Total Assets	646	730	790	740	793	877	1,017	1,083

NATHBIOGEN cash flows (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operating Activity	-23	9	1	17	38	75	27	-14
Cash from Investing Activity	-20	-14	-10	-20	-3	-27	-4	3
Cash from Financing Activity	20	6	16	-22	-2	-10	-11	-7
Net Cash Flow	-23	1	7	-25	34	38	12	-17
Free Cash Flow	-45	-6	-10	16	36	48	19	-17
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit	-47%	20%	2%	53%	80%	149%	52%	-25%

NATHBIOGEN shareholding pattern (%)
Category	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Promoters	45.59%	45.59%	45.59%	45.59%	45.59%	45.59%	45.59%	45.59%
FIIs	0.18%	0.19%	0.21%	0.41%	0.32%	0.31%	0.22%	0.26%
DIIs	4.37%	4.37%	3.94%	2.25%	0.76%	0.01%	0.01%	0.01%
Public	49.83%	49.83%	50.24%	51.73%	53.31%	54.08%	54.17%	54.13%
No. of Shareholders	35,423	35,056	34,911	34,207	34,122	33,550	33,031	32,564

NATHBIOGEN key ratios
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	191	159	147	136	152	139	122	89
Inventory Days	—	—	—	—	4,388	—	—	—
Days Payable	—	—	—	—	586	—	—	—
Cash Conversion Cycle	191	159	147	136	3,954	139	122	89
Working Capital Days	442	416	450	427	416	343	316	323
ROCE %	8%	9%	10%	5%	7%	7%	7%	7%

NATHBIOGENUpdated 18 Oct 2026, 14:34

Nath Bio-genes (i) Ltd

NATHBIOGENUpdated 18 Oct 2026, 14:34

Market Cap

₹262Cr.

Current Price

₹138

High / Low

₹207/126

Stock P/E

6.01

ROE5.70%

ROCE7.23%

Book Value₹363

Face Value₹10.0

Dividend Yield1.45%

About

Incorporated in 1993, Nath Bio-Genes Ltdis in the business of Production, Processing,and Marketing of Hybrid and GM Seeds[1]

Quarterly results

Last reported quarters₹ Cr.

Quarter	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Jun 2023	235	3	198	0	1	34	1	33	17.58
Sep 2023	23	2	17	0	1	2	18	2	0.85
Dec 2023	32	3	26	3	1	5	16	4	2.08
Mar 2024	43	1	39	1	1	4	16	3	1.69
Jun 2024	244	2	207	0	1	34	1	34	17.83
Sep 2024	32	3	26	0	1	3	-1	3	1.52
Dec 2024	37	3	29	0	1	4	30	3	1.4
Mar 2025	49	1	46	5	1	5	12	5	2.48
Jun 2025	280	3	250	4	1	30	2	29	15.37
Sep 2025	40	3	33	2	1	5	13	4	2.21
Dec 2025	66	4	57	4	1	8	11	7	3.8
Mar 2026	46	3	39	4	1	6	40	4	1.99
Jun 2026	323	4	288	3	1	33	2	33	17.19

Profit & loss

Annual statement₹ Cr.

Year	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Mar 2015	143	5	109	1	4	26	4	25	15.87
Mar 2016	127	6	103	1	4	15	6	14	8.85
Mar 2017	142	10	113	0	3	17	3	16	10.17
Mar 2018	171	10	131	1	1	30	2	29	15.48
Mar 2019	206	5	163	2	1	39	1	38	20.22
Mar 2020	246	7	191	2	1	49	-4	50	26.56
Mar 2021	271	9	204	2	3	57	2	56	29.29
Mar 2022	230	11	193	-87	3	-63	6	-67	-35.43
Mar 2023	234	10	185	1	3	36	3	35	18.51
Mar 2024	248	9	197	4	3	42	5	40	21.14
Mar 2025	265	10	212	4	4	44	4	42	22.17
Mar 2026	345	13	292	14	4	49	10	44	23.38
TTM	474	14	417	13	4	53	—	48	25.19

Shareholding pattern

As of Jun 2026%

Holder	Share
Promoters	45.59%
FIIs	0.26%
DIIs	0.01%
Public	54.13%

Shareholding trend

Ownership over time%

Quarter	Promoters	FIIs	DIIs	Public
Sep 2023	45.59%	0.22%	4.37%	49.81%
Dec 2023	45.59%	0.32%	4.37%	49.72%
Mar 2024	45.59%	0.27%	4.37%	49.76%
Jun 2024	45.59%	0.21%	4.37%	49.8%
Sep 2024	45.59%	0.18%	4.37%	49.83%
Dec 2024	45.59%	0.19%	4.37%	49.83%
Mar 2025	45.59%	0.21%	3.94%	50.24%
Jun 2025	45.59%	0.41%	2.25%	51.73%
Sep 2025	45.59%	0.32%	0.76%	53.31%
Dec 2025	45.59%	0.31%	0.01%	54.08%
Mar 2026	45.59%	0.22%	0.01%	54.17%
Jun 2026	45.59%	0.26%	0.01%	54.13%

Balance sheet

Assets & liabilities₹ Cr.

Period	Equity Capital	Reserves	Borrowings	Other Liabilities	Total Liabilities	Fixed Assets	Investments	Other Assets	Total Assets
Mar 2015	16	91	22	97	226	13	5	208	226
Mar 2016	16	105	59	87	267	30	5	231	267
Mar 2017	16	287	74	78	455	207	5	243	455
Mar 2018	19	450	33	69	571	211	5	355	571
Mar 2019	19	489	58	80	646	232	5	409	646
Mar 2020	19	539	70	102	730	246	5	479	730
Mar 2021	19	594	101	75	790	247	5	538	790
Mar 2022	19	523	93	105	740	245	5	490	740
Mar 2023	19	554	105	114	793	244	5	544	793
Mar 2024	19	592	108	158	877	249	6	622	877
Mar 2025	19	630	111	258	1017	250	6	761	1017
Mar 2026	19	670	122	272	1083	249	6	827	1083

Cash flows

Operating, investing & financing₹ Cr.

Period	Operating	Investing	Financing	Net cash flow
Mar 2015	6	-2	-4	-1
Mar 2016	-14	-17	30	0
Mar 2017	3	-4	5	5
Mar 2018	-47	-4	90	39
Mar 2019	-23	-20	20	-23
Mar 2020	9	-14	6	1
Mar 2021	1	-10	16	7
Mar 2022	17	-20	-22	-25
Mar 2023	38	-3	-2	34
Mar 2024	75	-27	-10	38
Mar 2025	27	-4	-11	12
Mar 2026	-14	3	-7	-17

Key ratios

Historical financial ratios

Category	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	114	130	133	175	191	159	147	136	152	139	122	89
Inventory Days	—	—	3,840	4,743	—	—	—	—	4,388	—	—	—
Days Payable	—	—	1,309	1,406	—	—	—	—	586	—	—	—
Cash Conversion Cycle	114	130	2,665	3,512	191	159	147	136	3,954	139	122	89
Working Capital Days	190	259	273	447	442	416	450	427	416	343	316	323
ROCE %	26%	14%	10%	9%	8%	9%	10%	5%	7%	7%	7%	7%

Frequently asked questions

Quick answers about this company's financials on Fincrux

What is the market cap of NATH BIO-GENES (I) LTD (NATHBIOGEN)?

The reported market capitalisation for NATH BIO-GENES (I) LTD (NATHBIOGEN) is ₹262Cr. on Fincrux. Figures may update with market data and filings.

What is the current share price of NATHBIOGEN?

The current price shown for NATH BIO-GENES (I) LTD (NATHBIOGEN) on Fincrux is ₹138 with a 52-week high/low of ₹207/126.

What is the P/E ratio of NATH BIO-GENES (I) LTD (NATHBIOGEN)?

The stock P/E for NATH BIO-GENES (I) LTD (NATHBIOGEN) is 6.01 on Fincrux, with ROE at 5.70% and ROCE at 7.23%.

What were NATHBIOGEN latest quarterly results?

For Jun 2026, NATH BIO-GENES (I) LTD (NATHBIOGEN) reported sales ₹323 Cr and net profit ₹33 Cr (figures in ₹ crore unless noted).

What are NATHBIOGEN annual sales and net profit?

For TTM, NATH BIO-GENES (I) LTD (NATHBIOGEN) shows sales of ₹474 Cr and net profit of ₹48 Cr on the Fincrux profit & loss statement.

Who owns NATH BIO-GENES (I) LTD (NATHBIOGEN)?

Latest shareholding for NATH BIO-GENES (I) LTD (NATHBIOGEN) on Fincrux: Promoters 45.59% (Jun 2026), FIIs 0.26% (Jun 2026), DIIs 0.01% (Jun 2026), Public 54.13% (Jun 2026), No. of Shareholders 32,564% (Jun 2026).

Where can I find NATH BIO-GENES (I) LTD (NATHBIOGEN) financials?

NATH BIO-GENES (I) LTD (NATHBIOGEN) financials on Fincrux include quarterly results, profit and loss, cash flow, balance sheet, key ratios, and shareholding patterns for NSE/BSE research.

Does Fincrux show NATHBIOGEN balance sheet and cash flow?

Yes. The NATH BIO-GENES (I) LTD (NATHBIOGEN) page on Fincrux includes balance sheet, cash flow statements, historical ratios, and ownership trends alongside quarterly and annual results.

Figures in ₹ crore unless noted. Data sourced for research and may lag filings.

Last updated 18 October 2026 at 14:34